Cambridge Investment Research Advisors, Inc. Clovis Oncology, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 17, 2022	BUY	$1.05 - $2.85 $11,093 - $30,110	10,565 Added 20.67%	61,667 $73,000
Q2 2022 Jul 13, 2022	BUY	$0.63 - $2.96 $6,024 - $28,303	9,562 Added 23.02%	51,102 $91,000
Q1 2022 May 12, 2022	SELL	$1.43 - $3.14 $10,510 - $23,079	-7,350 Reduced 15.03%	41,540 $83,000
Q4 2021 Feb 03, 2022	SELL	$2.7 - $4.76 $48,829 - $86,084	-18,085 Reduced 27.0%	48,890 $132,000
Q3 2021 Nov 02, 2021	BUY	$4.06 - $5.8 $12,931 - $18,473	3,185 Added 4.99%	66,975 $298,000
Q2 2021 Aug 10, 2021	BUY	$5.02 - $7.05 $166,879 - $234,363	33,243 Added 108.83%	63,790 $369,000
Q1 2021 May 07, 2021	BUY	$4.81 - $10.34 $146,931 - $315,855	30,547 New	30,547 $214,000
Q2 2020 Jul 27, 2020	SELL	$5.69 - $9.69 $64,621 - $110,049	-11,357 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$3.77 - $11.0 $42,815 - $124,927	11,357 New	11,357 $72,000

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account